Cardiovascular diseases are the leading cause for deaths globally. Recent studies show that allogeneic mesenchymal stem cells are able to restore endothelial function in heart failure by stimulating progenitor cells. Research such as this marks a significant turning point in the manner that heart failure is treated.
What causes heart failure
Heart failure is caused by a decrease in endothelial progenitor cell function, the circulating cells that give rise to the formation of new vessels, and vasodilation, the relaxation of muscles within cell walls to enable the widening of blood vessels. The self-renewing properties of mesenchymal stem cells mean that they enable endothelial progenitor cells to multiply. This improves the vascular reactivity, thus normalising the endothelial function in patients.
There are two types of stem cells that can be used. Autologous stem cells come from the patients themselves, whereas allogeneic stem cells are those taken from an external donor. It has been found that allogeneic, not autologous, stem cells can be used to treat heart failure.
Autologous stem cells come from the patient’s own system so they may be negatively altered, thus making the cells not as effective as allogeneic cells.
Stem cells show promise for the future of heart failure treatments. In many cases, stem cell treatments have been successfully carried out on patients who were told they had no hope. Currently, stem cells seem to be the only way to treat many diseases and conditions. At Beike Biotechnology, we currently offer treatments for ischemic heart disease, including myocardial infarction, heart failure and cardio myopathy.